Vivtex Revenue and Competitors
Estimated Revenue & Valuation
- Vivtex's estimated annual revenue is currently $1.9M per year.
- Vivtex's estimated revenue per employee is $155,000
Employee Data
- Vivtex has 12 Employees.
- Vivtex grew their employee count by -25% last year.
Vivtex's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Co-Founder and Chief Scientific Officer | Reveal Email/Phone |
2 | CEO/Co-Founder | Reveal Email/Phone |
3 | CEO | Reveal Email/Phone |
4 | CFO | Reveal Email/Phone |
5 | SVP Chemistry Manufacturing & Controls (CMC) and Nonclinical Developmen | Reveal Email/Phone |
6 | SVP Drug Development | Reveal Email/Phone |
7 | Associate Director - Bioanalysis | Reveal Email/Phone |
8 | Pre-Clinical Project Manager | Reveal Email/Phone |
9 | Research Associate III | Reveal Email/Phone |
Vivtex Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Vivtex?
Vivtex strives to transform drug development using a new platform technology called gastrointestinal tract organ robotic interface system (GI-ORISâ„¢) that enables robotic screening with fully intact and functional organs. GI-ORISâ„¢ technology was developed in the Langer lab at MIT and can be used for various applications (e.g. oral delivery of biologics, drug toxicity mitigation, spatial and temporal drug delivery). Vivtex leverages these unique capabilities of the GI-ORISâ„¢ to develop new oral therapeutics. Vivtex's mission is to serve patients by increasing the efficacy, safety and adherence of existing and novel therapies. The company is in preclinical stage and has multiple drug development programs including reformulations of existing drugs as well as new chemical entities. The company was co-founded by Professor Robert Langer (MIT), Dr. Giovanni Traverso (Harvard Medical School), Doug Eby (Cambridge Science), and Thomas von Erlach.
keywords:N/A
N/A
Total Funding
12
Number of Employees
$1.9M
Revenue (est)
-25%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $3.5M | 12 | 0% | $16.4M |
#2 | N/A | 12 | 9% | N/A |
#3 | $1.5M | 12 | 0% | N/A |
#4 | $1.8M | 12 | -43% | N/A |
#5 | $1.3M | 12 | -8% | N/A |